STOCK TITAN

Galectin Therapeutics Inc - GALT STOCK NEWS

Welcome to our dedicated news page for Galectin Therapeutics (Ticker: GALT), a resource for investors and traders seeking the latest updates and insights on Galectin Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Galectin Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Galectin Therapeutics's position in the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.13%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.35%
Tags
earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.85%
Tags
earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.3%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.86%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.98%
Tags
earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.15%
Tags
conferences
Galectin Therapeutics Inc

Nasdaq:GALT

GALT Rankings

GALT Stock Data

147.82M
42.64M
31.07%
11.69%
3.46%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Berkeley Lake

About GALT

galectin therapeutics (nasdaq: galt) is applying its leadership in galectin science and drug development to create new therapies for fibrotic disease and cancer. drug candidates based on the company’s unique carbohydrate technology target galectin proteins which are key mediators of biologic and pathologic function. we use naturally occurring carbohydrate polymers with galactose residues to create complex carbohydrates with specific molecular weights. using these unique carbohydrate-based candidate compounds that bind and inhibit galectin proteins, we are pursuing therapies for indications where galectins have a demonstrated role in the pathogenesis of a particular disease. we focus on diseases with serious, life threatening consequences to patients, and those where current treatment options are limited. our strategy is to establish clinical development approaches that add value to the company in the shortest time possible, and to seek partners as the program advances and requires much